## **What are prescription monitoring programs?**
A prescription monitoring program (PMP) or prescription monitoring drug program (PDMP) operates as a state-run electronic database that tracks the dispensing of prescription drugs to enhance prescription management and prevent misuse (Centers for Disease Control and Prevention, 2024). These programs collect data on prescriptions—usually for Schedule II-V drugs—so health professionals, including pharmacists and prescribers, can make informed decisions (Wilson et. al., 2019). They also help identify possible drug interactions and improve the effectiveness and safety of prescribed medications.
When PMPs integrate with health IT systems, they streamline patient prescription monitoring and ensure safe prescribing practices. Many states also share data across state lines, enabling providers to identify patients who engage in “doctor shopping” for controlled substances.
PMPs serve as a trusted source of drug information for health system pharmacists and consumers, ensuring compliance with FDA regulations and promoting patient safety. They also support brand and generic drug oversight by highlighting usage patterns and risk factors. With strict privacy measures, only authorized contacts, such as law enforcement during active investigations, can access this database, ensuring accountability in prescribing practices.
## **Healthcare provider PMP roles and responsibilities**
Healthcare providers play a critical role in using PMP data to ensure patients’ safety and improve the management of controlled substances. They must incorporate PMP insights into their prescribing decisions to reduce risk and enhance effectiveness.
Providers review PMP records before prescribing or dispensing prescription drugs or even certain over the counter medicines when potential misuse or drug interactions are a concern (D’Souza & Eldridge, 2024). This process helps identify behaviors such as obtaining multiple prescriptions from different providers. By leveraging this information, providers can make prescribing choices that protect patients and meet state and federal regulations.
Providers also maintain accurate prescription records, ensuring proper monitoring of medications throughout treatment. They educate patients about correct use, safety, and the potential risks of dependency. If concerns arise, they coordinate care with specialists or addiction treatment programs.
To stay compliant, providers regularly update data, report as required, and use PMP insights to adjust treatment plans. They may also recommend non-controlled or generic alternatives to reduce costs for consumers while maintaining effectiveness and safety.
## **Benefits of prescription monitoring programs**
PMPs offer several benefits for health professionals and consumers:
### **Reduction in prescription misuse and diversion**
PMPs track patients’ medication histories in real time, allowing providers to detect “doctor shopping” or excessive prescribing. Reviewing this database enables early intervention to prevent prescription misuse and maintain safety.
### **Improved clinical decision-making**
PMPs provide health professionals and pharmacists with comprehensive drug information, enabling them to spot potential drug interactions and avoid harmful combinations. With FDA-aligned data integrated into office systems, providers make safer prescribing choices that protect patients.
### **Enhanced patient safety**
By highlighting risk factors for opioid misuse or overdose, PMPs help health professionals design safer prescribing strategies. This supports public health by reducing preventable harm and encouraging the use of generic or alternative treatments when possible.
## **Implementing PMPs in clinical practice**
Implementing PMPs requires a technology-driven, evidence-based approach. Providers first register for PMP access, ensuring they understand how to use the database efficiently.
Integrating PMP data into electronic health records (EHRs) gives providers real-time access during prescribing decisions. Clinical teams establish standardized workflows for reviewing patient medication histories, checking for drug interactions, and confirming the safety and effectiveness of treatments.
Ongoing training ensures health professionals can interpret PMP data, recognize high-risk prescribing patterns, and make informed drug choices. Regular audits, along with news updates from FDA and other trusted sources, help maintain compliance.
## **State-specific PMP information**
PMP rules vary by state:
- **Iowa**: Reports on Schedule II-V prescription drugs, naloxone, and some over the counter medicines (Iowa Department of Inspections, Appeals, & Licensing, 2024). Only authorized health professionals can access the database.
- **Washington**: Offers multi-state search capabilities so pharmacists and prescribers can review drug histories across borders (Washington State Department of Health, n.d.).
- **Virginia**: Tracks Schedule II-IV substances, select Schedule V drugs, naloxone, and cannabis products. Also supports law enforcement investigations (Virginia Department of Health Professions, n.d.).
- **Oklahoma**: Runs the only real-time PMP, requiring providers to check data before prescribing certain medications and every 180 days for refills (Oklahoma Department of Mental Health & Substance Abuse Services, n.d.).
## **Challenges and limitations of PMPs**
PMPs face challenges in data sharing, funding, and provider adoption. Some states lack resources for full EHR integration or interstate database connections (Ajami & Bagheri-Tadi, 2013). Others limit access to certain health professionals, which can hinder drug misuse prevention.
Change management remains an issue as some providers resist workflow changes. Time, cost, and training requirements can also slow adoption. Furthermore, drug information updates from FDA and trusted sources must be incorporated promptly to maintain effectiveness.
## **Key takeaways**
PMPs strengthen prescription management by giving health professionals a trusted source of drug information that supports safe prescribing, prevents misuse, and protects patients. They enhance health outcomes, improve effectiveness, and reduce risk by ensuring pharmacists, providers, and consumers have access to timely, accurate data.
As these programs evolve, integrating FDA updates, improving database connectivity, and keeping news and guidance current will help PMPs remain a vital part of the health system.
## **References**
Ajami, S., & Bagheri-Tadi, T. (2013). Barriers for adopting electronic health records (EHRs) by physicians. Acta Informatica Medica, 21(2), 129–134. https://doi.org/10.5455/aim.2013.21.129-134
Centers for Disease Control and Prevention. (2024, May 6). Prescription drug monitoring programs (PDMPs). Overdose prevention. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/prescription-drug-monitoring-programs.html
D’Souza, R. S., & Eldridge, J. S. (2024, November 14). Prescription drug monitoring program. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532299/
Iowa Department of Inspections, Appeals, & Licensing. (2024, May 23). Prescription monitoring program (PMP). Department of Inspections, Appeals, & Licensing. https://dial.iowa.gov/licenses/medical/pharmacy/prescription-monitoring-program-pmp
Oklahoma Department of Mental Health & Substance Abuse Services. (n.d.). The Oklahoma prescription monitoring program (PMP). (Retrieved April 29, 2024) https://oklahoma.gov/content/dam/ok/en/odmhsas/documents/a0001/pmp-overview-and-interpreting-pmp-indicators.pdf
Virginia Department of Health Professions. (n.d.). Prescription monitoring program. https://www.dhp.virginia.gov/PractitionerResources/PrescriptionMonitoringProgram/
Washington State Department of Health. (n.d.). Prescription monitoring program (PMP). https://doh.wa.gov/public-health-provider-resources/healthcare-professions-and-facilities/prescription-monitoring-program-pmp
Wilson, M. N., Hayden, J. A., Rhodes, E., Robinson, A., & Asbridge, M. (2019). Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: A systematic review. The Journal of Pain, 20(12), 1383–1393. https://doi.org/10.1016/j.jpain.2019.04.007
